Literature DB >> 21941367

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.

T Holien1, T K Våtsveen, H Hella, C Rampa, G Brede, L A G Grøseth, M Rekvig, M Børset, T Standal, A Waage, A Sundan.   

Abstract

Bone morphogenetic proteins (BMPs) have been shown to induce apoptosis and growth arrest in myeloma cells. However, the molecular mechanisms behind these events are not known. The MYC oncogene is a master regulator of cell growth and protein synthesis and MYC overexpression has been proposed to be associated with the progression of multiple myeloma. Here, we show that BMP-induced apoptosis in myeloma cells is dependent on downregulation of MYC. Moreover, the results suggest that targeting the MYC addiction in multiple myeloma is an efficient way of killing a majority of primary myeloma clones. We also found that myeloma cells harboring immunoglobulin (IG)-MYC translocations evaded BMP-induced apoptosis, suggesting a novel way for myeloma cells to overcome potential tumor suppression by BMPs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21941367     DOI: 10.1038/leu.2011.263

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  21 in total

1.  Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Authors:  Muhammad Zahoor; Marita Westhrin; Kristin Roseth Aass; Siv Helen Moen; Kristine Misund; Katarzyna Maria Psonka-Antonczyk; Mariaserena Giliberto; Glenn Buene; Anders Sundan; Anders Waage; Anne-Marit Sponaas; Therese Standal
Journal:  Blood Adv       Date:  2017-12-13

2.  Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Authors:  Zijun Y Xu-Monette; Bouthaina S Dabaja; Xiaoxiao Wang; Meifeng Tu; Ganiraju C Manyam; Alexander Tzankov; Yi Xia; Li Zhang; Ruifang Sun; Carlo Visco; Karen Dybkaer; Lihui Yin; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Ben M Parsons; Xiaoying Zhao; Jane N Winter; Miguel A Piris; Timothy J McDonnell; Roberto N Miranda; Yong Li; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2015-11-06       Impact factor: 7.842

3.  Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.

Authors:  Alboukadel Kassambara; Dirk Hose; Jérôme Moreaux; Thierry Rème; Jennifer Torrent; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

4.  Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.

Authors:  Oddrun Elise Olsen; Karin Fahl Wader; Hanne Hella; Anne Kærsgaard Mylin; Ingemar Turesson; Ingerid Nesthus; Anders Waage; Anders Sundan; Toril Holien
Journal:  Cell Commun Signal       Date:  2015-06-06       Impact factor: 5.712

5.  Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Authors:  O E Olsen; K F Wader; K Misund; T K Våtsveen; T B Rø; A K Mylin; I Turesson; B F Størdal; S H Moen; T Standal; A Waage; A Sundan; T Holien
Journal:  Blood Cancer J       Date:  2014-03-21       Impact factor: 11.037

6.  10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells.

Authors:  Qitian Mu; Qiuling Ma; Shasha Lu; Ting Zhang; Mengxia Yu; Xin Huang; Jian Chen; Jie Jin
Journal:  Oncol Lett       Date:  2014-06-24       Impact factor: 2.967

7.  Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.

Authors:  Arnold Bolomsky; Dirk Hose; Martin Schreder; Anja Seckinger; Susanne Lipp; Bernard Klein; Daniel Heintel; Heinz Ludwig; Niklas Zojer
Journal:  J Hematol Oncol       Date:  2015-02-08       Impact factor: 17.388

Review 8.  Receptor binding competition: A paradigm for regulating TGF-β family action.

Authors:  Erik Martinez-Hackert; Anders Sundan; Toril Holien
Journal:  Cytokine Growth Factor Rev       Date:  2020-10-06       Impact factor: 7.638

9.  Oncogene addiction to c-MYC in myeloma cells.

Authors:  Toril Holien; Anders Sundan
Journal:  Oncotarget       Date:  2012-08

10.  Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma.

Authors:  Kanutte Huse; Maren Bakkebø; Sébastien Wälchli; Morten P Oksvold; Vera I Hilden; Lise Forfang; May L Bredahl; Knut Liestøl; Ash A Alizadeh; Erlend B Smeland; June H Myklebust
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.